Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olivier Rixe

Showing results (1-10 of 84) with videos related to

Pageof 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2007
Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?Olivier Rixe, Tito Fojo
Targeted Oncology|August 13, 2010
Renal cell carcinoma: ten years of significant advancesOlivier Rixe, Brian Rini
Targeted Oncology|October 10, 2019
Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical TrialsXavier Paliard, Olivier Rixe
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 15, 2010
Axitinib (AG-013736)Ronan Joseph Kelly, Olivier Rixe
Targeted Oncology|October 31, 2009
Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptorRonan J Kelly, Olivier Rixe
Expert Opinion on Drug Discovery|June 4, 2015
Axitinib: from preclinical development to future clinical perspectives in renal cell carcinomaYousef Zakharia, Kais Zakharia, Olivier Rixe
Journal of Neuro-Oncology|July 20, 2007
Regression of brain metastases of renal cell carcinoma with antiangiogenic therapyFrédéric Thibault, Bertrand Billemont, Olivier Rixe
The New England Journal of Medicine|August 30, 2008
Scrotal cutaneous side effects of sunitinibBertrand Billemont, Stéphane Barete, Olivier Rixe
The New England Journal of Medicine|September 28, 2007
Macrocytosis due to treatment with sunitinibBertrand Billemont, Hassane Izzedine, Olivier Rixe
Targeted Oncology|May 8, 2009
Renal toxicity of targeted therapiesRonan J Kelly, Bertrand Billemont, Olivier Rixe
Pageof 9

Showing results (1-10 of 84) with videos related to

Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2007
Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?Olivier Rixe, Tito Fojo
Targeted Oncology|August 13, 2010
Renal cell carcinoma: ten years of significant advancesOlivier Rixe, Brian Rini
Targeted Oncology|October 10, 2019
Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical TrialsXavier Paliard, Olivier Rixe
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 15, 2010
Axitinib (AG-013736)Ronan Joseph Kelly, Olivier Rixe
Targeted Oncology|October 31, 2009
Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptorRonan J Kelly, Olivier Rixe
Expert Opinion on Drug Discovery|June 4, 2015
Axitinib: from preclinical development to future clinical perspectives in renal cell carcinomaYousef Zakharia, Kais Zakharia, Olivier Rixe
Journal of Neuro-Oncology|July 20, 2007
Regression of brain metastases of renal cell carcinoma with antiangiogenic therapyFrédéric Thibault, Bertrand Billemont, Olivier Rixe
The New England Journal of Medicine|August 30, 2008
Scrotal cutaneous side effects of sunitinibBertrand Billemont, Stéphane Barete, Olivier Rixe
The New England Journal of Medicine|September 28, 2007
Macrocytosis due to treatment with sunitinibBertrand Billemont, Hassane Izzedine, Olivier Rixe
Targeted Oncology|May 8, 2009
Renal toxicity of targeted therapiesRonan J Kelly, Bertrand Billemont, Olivier Rixe
Pageof 9